NYSE:MYOV - Myovant Sciences Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Myovant Sciences Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $15.05 -0.68 (-4.32 %) (As of 12/15/2019 04:00 PM ET) Add Compare Today's Range$14.49Now: $15.05▼$15.9850-Day Range$4.34MA: $10.71▼$19.0452-Week Range$4.14Now: $15.05▼$26.02Volume1.99 million shsAverage Volume6.66 million shsMarket Capitalization$1.35 billionP/E RatioN/ADividend YieldN/ABeta2.13 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. Read More… Industry, Sector and Symbol Stock Exchange NYSE Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNYSE:MYOV Previous SymbolNASDAQ:MYOV CUSIPN/A CIK1679082 Webhttp://www.myovant.com/ Phone44-20-7400-3347Debt Debt-to-Equity Ratio5.88 Current Ratio2.79 Quick Ratio2.79Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.06 per share Price / Book250.83Profitability EPS (Most Recent Fiscal Year)($4.09) Net Income$-273,550,000.00 Net MarginsN/A Return on Equity-768.49% Return on Assets-140.39%Miscellaneous Employees86 Outstanding Shares89,620,000Market Cap$1.35 billion Next Earnings Date2/6/2020 (Estimated) OptionableNot Optionable Receive MYOV News and Ratings via Email Sign-up to receive the latest news and ratings for MYOV and its competitors with MarketBeat's FREE daily newsletter. MYOV Rates by TradingView Myovant Sciences (NYSE:MYOV) Frequently Asked Questions What is Myovant Sciences' stock symbol? Myovant Sciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "MYOV." How were Myovant Sciences' earnings last quarter? Myovant Sciences Ltd (NYSE:MYOV) posted its earnings results on Tuesday, November, 12th. The company reported ($0.79) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.73) by $0.07. View Myovant Sciences' Earnings History. When is Myovant Sciences' next earnings date? Myovant Sciences is scheduled to release their next quarterly earnings announcement on Thursday, February 6th 2020. View Earnings Estimates for Myovant Sciences. What price target have analysts set for MYOV? 8 analysts have issued 1-year price objectives for Myovant Sciences' stock. Their forecasts range from $20.00 to $34.00. On average, they expect Myovant Sciences' stock price to reach $26.00 in the next twelve months. This suggests a possible upside of 72.8% from the stock's current price. View Analyst Price Targets for Myovant Sciences. What is the consensus analysts' recommendation for Myovant Sciences? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Myovant Sciences in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Myovant Sciences. Has Myovant Sciences been receiving favorable news coverage? News stories about MYOV stock have been trending neutral recently, InfoTrie Sentiment reports. InfoTrie rates the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Myovant Sciences earned a media sentiment score of 0.2 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for Myovant Sciences. Are investors shorting Myovant Sciences? Myovant Sciences saw a drop in short interest in the month of November. As of November 29th, there was short interest totalling 3,140,000 shares, a drop of 28.8% from the November 14th total of 4,410,000 shares. Based on an average daily volume of 2,350,000 shares, the short-interest ratio is currently 1.3 days. Approximately 9.8% of the company's stock are sold short. View Myovant Sciences' Current Options Chain. Who are some of Myovant Sciences' key competitors? Some companies that are related to Myovant Sciences include Ascendis Pharma A/S (ASND), Global Blood Therapeutics (GBT), BridgeBio Pharma (BBIO), Mirati Therapeutics (MRTX), FibroGen (FGEN), United Therapeutics (UTHR), Nektar Therapeutics (NKTR), Intercept Pharmaceuticals (ICPT), SAGE Therapeutics (SAGE), Blueprint Medicines (BPMC), Taro Pharmaceutical Industries (TARO), Evotec (EVTCY), Alkermes (ALKS), GW Pharmaceuticals PLC- (GWPH) and HUTCHISON CHINA/S (HCM). What other stocks do shareholders of Myovant Sciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Myovant Sciences investors own include Amarin (AMRN), Exelixis (EXEL), Fate Therapeutics (FATE), Revance Therapeutics (RVNC), Viking Therapeutics (VKTX), Clovis Oncology (CLVS), Crispr Therapeutics (CRSP), Uniqure (QURE), SCYNEXIS (SCYX) and Energy Transfer LP Unit (ET). Who are Myovant Sciences' key executives? Myovant Sciences' management team includes the folowing people: Dr. Lynn Seely, Principal Exec. Officer, Pres & Exec. Director (Age 60)Mr. Frank L. Karbe, Chief Financial Officer (Age 51)Mr. Matthew Lang, Gen. Counsel & Sec. (Age 43)Ms. Julie Tran MBA, MSHR, Sr. VP of HRMs. Marianne L. Romeo, Head of Global Transactions & Risk Management (Age 51) When did Myovant Sciences IPO? (MYOV) raised $176 million in an initial public offering on Thursday, October 27th 2016. The company issued 13,000,000 shares at $12.00-$15.00 per share. Citigroup, Cowen and Company, Evercore ISI and Barclays served as the underwriters for the IPO and JMP Securities and Baird were co-managers. Who are Myovant Sciences' major shareholders? Myovant Sciences' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Eventide Asset Management LLC (5.24%), Great Point Partners LLC (0.36%), Point72 Asset Management L.P. (0.23%), LVW Advisors LLC (0.13%), State Street Corp (0.06%) and Millennium Management LLC (0.05%). Company insiders that own Myovant Sciences stock include Andrew Lo, Ferreira Juan Camilo Arjona, Frank Karbe, Holdings Ltd Dexxon, Kathleen Sebelius, Mark Altmeyer, Pharmaceuticals Interna Takeda and Sciences Ltd Roivant. View Institutional Ownership Trends for Myovant Sciences. Which institutional investors are selling Myovant Sciences stock? MYOV stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P. and Millennium Management LLC. View Insider Buying and Selling for Myovant Sciences. Which institutional investors are buying Myovant Sciences stock? MYOV stock was purchased by a variety of institutional investors in the last quarter, including Eventide Asset Management LLC, Great Point Partners LLC, LVW Advisors LLC, State Street Corp, Virginia Retirement Systems ET AL, Tower Research Capital LLC TRC and Barclays PLC. Company insiders that have bought Myovant Sciences stock in the last two years include Andrew Lo, Frank Karbe, Holdings Ltd Dexxon, Kathleen Sebelius, Mark Altmeyer, Pharmaceuticals Interna Takeda and Sciences Ltd Roivant. View Insider Buying and Selling for Myovant Sciences. How do I buy shares of Myovant Sciences? Shares of MYOV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Myovant Sciences' stock price today? One share of MYOV stock can currently be purchased for approximately $15.05. How big of a company is Myovant Sciences? Myovant Sciences has a market capitalization of $1.35 billion. The company earns $-273,550,000.00 in net income (profit) each year or ($4.09) on an earnings per share basis. Myovant Sciences employs 86 workers across the globe.View Additional Information About Myovant Sciences. What is Myovant Sciences' official website? The official website for Myovant Sciences is http://www.myovant.com/. How can I contact Myovant Sciences? Myovant Sciences' mailing address is 11-12 ST. JAMES`S SQUARE SUITE 1 3RD FLOOR, LONDON X0, SW1Y 4LB. The company can be reached via phone at 44-20-7400-3347 or via email at [email protected] MarketBeat Community Rating for Myovant Sciences (NYSE MYOV)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 187 (Vote Outperform)Underperform Votes: 175 (Vote Underperform)Total Votes: 362MarketBeat's community ratings are surveys of what our community members think about Myovant Sciences and other stocks. Vote "Outperform" if you believe MYOV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MYOV will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/15/2019 by MarketBeat.com StaffFeatured Article: What is the definition of a trade war?